Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.

NCT04742413 is registered in ClinicalTrials.gov with Angelini Farmacéutica as lead sponsor.

NCT NCT04742413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04742413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.
Lead sponsor
Angelini Farmacéutica
Phase
Observational
Overall status
Terminated
Start date
December 29, 2020
Completion date
March 15, 2022
Enrollment
9 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia